The Rapamycin Dog Aging Study: Could a Drug Help Dogs Live Longer?

The biggest frustration of dog ownership is how short their lives are. A golden retriever averages 10 to 12 years. A Great Dane, 7 to 10. Even small breeds rarely exceed 16. The Dog Aging Project, the largest-ever study of companion dog health and aging, is investigating whether a drug called rapamycin could extend not just how long dogs live, but how well they live in their later years.

In January 2025, the project received a five-year, $7 million grant from the National Institute on Aging to expand its clinical trial, known as TRIAD — the Test of Rapamycin in Aging Dogs. With the grant came renewed urgency to finish enrolling participants and begin the medication phase by spring 2026.

What Is Rapamycin?

Rapamycin is an immunosuppressant drug originally used to prevent organ transplant rejection. It works by inhibiting the mTOR pathway — a cellular signaling network that regulates growth, metabolism, and aging. In laboratory organisms ranging from yeast to mice, rapamycin consistently extends lifespan, sometimes dramatically.

What makes rapamycin different from anti-aging supplements and wellness trends is the depth of evidence behind it. Multiple independent laboratories across decades of research have confirmed its life-extending effects in controlled studies. The question has never been whether rapamycin works in lab organisms, but whether those effects translate to long-lived, genetically diverse mammals living in real-world conditions.

Dogs, sharing our homes, diets, and environments, are the ideal bridge between lab mice and humans.

How the TRIAD Study Works

The TRIAD trial is a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter study. In plain language: half the dogs receive low-dose rapamycin once weekly, and half receive a placebo. Neither the owners nor the veterinarians know which dogs get which treatment until the study concludes.

Eligible dogs must be at least seven years old, healthy, and enrolled in the broader Dog Aging Project. The treatment period lasts one year, followed by a two-year observation period. The study targets enrollment of 580 dogs across multiple veterinary centers, with over 180 already enrolled as of early 2025.

The primary endpoint is lifespan — do rapamycin-treated dogs live longer than placebo dogs? Secondary endpoints include improvements in healthspan metrics: arthritis severity, kidney function, cardiac health, cognitive decline, and cancer incidence. If rapamycin extends life but those extra months are spent in pain and decline, the drug would fail its most important test.

Why Dogs Make Better Aging Models Than Mice

Laboratory mice live two to three years in controlled environments, eating standardized diets, and lacking the genetic diversity of natural populations. Extending a mouse’s life from 24 to 30 months is scientifically interesting but raises questions about relevance to more complex organisms.

Dogs are different in every relevant dimension. They are genetically diverse. They eat varied diets. They experience stress, joy, illness, and environmental exposures similar to their human families. They develop age-related diseases — cancer, heart disease, cognitive decline, arthritis — that closely parallel human aging.

A companion dog study has statistical power that no mouse study can match, because it reflects genuine biological aging in a realistic setting. If rapamycin extends healthy lifespan in dogs, the implications for human medicine are direct and substantial.

What Early Results Suggest

The Dog Aging Project has not yet published definitive TRIAD results, but the broader project — which tracks over 45,000 companion dogs — has generated preliminary observations.

The AVMA reported that early data from retired sled dogs in the study indicate aging may differ between male and female dogs, a certain drug may slow the aging clock, and mortality may be linked to a specific physiological pattern. These early signals are promising but require the full trial dataset to confirm.

Importantly, the low-dose, once-weekly rapamycin regimen used in TRIAD has been well-tolerated in enrolled dogs. Unlike the higher doses used for transplant rejection, low-dose rapamycin does not appear to cause significant immunosuppression. Gastrointestinal side effects have been mild and manageable.

What This Means for Your Senior Dog Now

Rapamycin is not yet approved or recommended for general use in dogs. Dog owners should not attempt to source rapamycin independently or ask their veterinarian to prescribe it off-label based on preliminary research. The TRIAD trial exists precisely because the safety and efficacy in companion dogs have not been established.

However, the science of dog aging offers actionable guidance right now.

Regular veterinary care accelerates early detection — Senior dog care should include biannual wellness exams with bloodwork, urinalysis, and a thorough physical. Catching kidney decline, thyroid dysfunction, or early cancer before symptoms appear dramatically improves outcomes.

Maintain mobility through exercise — Joint stiffness and muscle loss are among the first visible signs of aging. Continuing age-appropriate exercise preserves mobility, maintains healthy weight, and supports cardiovascular health. Our dog exercise guide by breed helps calibrate activity levels for senior dogs.

Cognitive enrichment slows mental decline — Puzzle toys, training sessions, scent work, and novel experiences stimulate aging brains. Dogs showing signs of cognitive dysfunction syndrome — disorientation, altered sleep patterns, decreased interaction — benefit from mental stimulation alongside veterinary management.

Nutrition matters more with age — Senior dogs may benefit from diets higher in protein to maintain muscle mass, supplemented with omega-3 fatty acids for joint and cognitive support. Discuss nutritional adjustments with your veterinarian, and understand what is in your dog’s food with our dog food labels guide.

Weight management is the simplest intervention — Keeping your dog lean is the single most evidence-based thing you can do to extend their healthy lifespan. A landmark Purina study showed that lean dogs lived an average of 1.8 years longer than their overfed littermates. See our dog weight management guide for practical strategies.

The Future of Dog Longevity

The Dog Aging Project represents a new era in veterinary science — one where companion dogs are not just patients but research partners whose health data improves understanding of aging across species. Whether rapamycin proves to be the breakthrough drug or simply one stepping stone toward more effective interventions, the project is generating insights that will benefit dogs and humans alike for decades.

Enrollment at participating veterinary centers continues. If you have a healthy dog aged seven or older, visit dogagingproject.org to learn about participation.

Sources

1. Dog Aging Project receives $7M NIH grant to expand rapamycin trial — Texas A&M — accessed March 26, 2026
2. Test of Rapamycin in Aging Dogs (TRIAD) study design — PubMed — accessed March 26, 2026
3. $7M grant rescues dog study investigating rapamycin for canine aging — AVMA — accessed March 26, 2026
4. Dog Aging Project TRIAD clinical trial information — accessed March 26, 2026